Redirecting to https://apnews.com/press-release/pr-newswire/dizals-zegfrovy-sunvozertinib-new-drug-application-accepted-and-granted-priority-review-by-china-national-medical-products-administration-for-first-line-treatment-of-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-2d0c8542b7654e41603af08dc09a2f87